TANG ET AL, BMJ: Favourable data for hydroxychloroquine removed between study’s draft and final print

Source: Mediterranee Infection

Why this discrepancy between the preprint version and the version published in the BMJ?

Tang et al. – Data (text and figures) evidencing a favorable effect of HCQ removed in the final published version (version 2 on MedRxiv and final version on BMJ)

Version 1:
 https://www.medrxiv.org/content/10.1101/2020.04.10.20060558v1?versioned=true

Version 2:
 https://www.medrxiv.org/content/10.1101/2020.04.10.20060558v2

BMJ Final
https://www.bmj.com/content/369/bmj.m1849

blank
blank
blank
Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

American Hero: Ralph C. Lorigo Fights for Client Rights Including Access to Ivermectin for COVID-19 Patients At Risk

Lorigo shared with TrialSite that once doctors learn of all of the studies around the world, and start doing their own homework, they become more open-minded, factoring in the risk-reward analysis. Especially if elderly high risk patients present advanced COVID-19, Lorigo has personally seen the drug potentially contribute to saving the lives of clients. Interestingly, the attorney reports that it would appear that hospital administrations are the most recalcitrant to the idea, even if the patients and the ICU doctor are in support.

Read More »